Chen et al. find that a specific B cell subset is associated with immunotherapy resistance in bladder cancer.
IGLL5+ B cells interact with HEVs through IGLL5-LTβR signaling, leading to the impairment of TLSs formation in humanized mouse models. This interaction presents a promising therapeutic target for overcoming immunotherapy resistance in bladder cancer.
Cancer Cell published a clinical update in Oncology on 08 Jan 2026.
The item focuses on B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.
Review the original article for the full source wording and details.